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-Galactosylceramide (-GalCer) is the prototype compound for
studying the presentation of glycolipids on CD1d molecules to
natural killer T (NKT) lymphocytes. A single i.v. dose of glycolipid
triggers a cascade of events involving the production of several
cytokines over the course of a day, a short-lived activation of NKT
and natural killer (NK) cells, and a more prolonged adaptive T cell
immune response if certain antigens are given together with
-GalCer. We find that a recently described analogue, -C-galac-
tosylceramide (-C-GalCer), more potently induces these innate
and adaptive immune responses in mice. -C-GalCer acts as a more
effective trigger for IL-12 and IFN- production, although it mini-
mally elicits IL-4 and TNF- release into the serum. Also, -C-GalCer
better mobilizes NKT and natural killer cells to resist B16 mela-
noma. To help understand these effects, we find that -C-GalCer
binds more stably to dendritic cells than -GalCer and that den-
dritic cells loaded with -C-GalCer induce larger and more long
lasting NKT cell responses in vivo. When glycolipid is targeted to
dendritic cells in spleen together with antigens in dying cells, such
as irradiated tumor cells, -C-GalCer is active as an adjuvant for T
cell-mediated immunity at lower doses, just 20 ng per mouse,
where it is also able to up-regulate the required CD40L costimu-
latory molecule on NKT cells. Therefore, -C-GalCer represents a
glycolipid that binds more stably to dendritic cells and acts as a
more effective link between innate and adaptive immunity in vivo.
immune therapy  maturation  natural killer T  CD40L
The glycolipid, -galactosylceramide (-GalCer), is a naturalproduct of mollusks and is presented on CD1d molecules to
the invariant V14 T cell receptor on natural killer T (iNKT)
cells (1). The presentation of glycolipid on CD1d molecules to
iNKT cells results in a cascade of cellular events that is able to
provide resistance to tumors. For example, -GalCer-activated
iNKT cells recognize endogenous glycolipids on tumor cells and
kill them, e.g., human myeloma (2) and glioma (3). Dendritic
cells (DCs), when they present -GalCer to iNKT cells, produce
IL-12, which mobilizes natural killer (NK) cells that also have
antitumor effects (4). -GalCer additionally acts as an adjuvant
for adaptive T cell immunity (5). This adjuvant effect means that
DCs, upon capturing tumor antigens, are able to differentiate or
mature in response to iNKT cells and then induce Th1-type
CD4 and cytolytic CD8 T cells (6–8). Given these outcomes
for tumor immunity, it is important to identify analogues that
influence the immune outcome of glycolipid administration,
particularly to improve the clinical efficacy of CD1d-binding
glycolipids.
Several previously uncharacterized glycolipid ligands for
CD1d now have been identified. The iNKT cells recognize an
endogenous ligand, lysosomal glycolipid isoglobotrihexosylcer-
amide, such that mice genetically deficient in the lysosomal
glycosphingolipid degrading enzyme -hexosaminidase
(Hex/) have severely reduced iNKT cell numbers (9). An-
other natural ligand is disialoganglioside GD3. This ligand is
expressed on melanomas and is presented to iNKT cells when
DCs process tumor cells (10). Microbial glycolipids also are
presented by CD1d on hex/ antigen-presenting cells, includ-
ing -glucuronosylceramide from the Sphingomonas cell wall
(11, 12), -galacturonosylceramides from Sphingomonas wit-
tichii, and glycolipids from Borrelia burgdorferi, the Lyme disease
spirochete (13).
CD1d-binding glycolipid analogs, including sphingolipids and
sulfatide variants, also have been synthesized. These synthesized
ligands induce mouse and human NKT cells to secrete IFN- and
IL-4 (13). One of these glycolipids, -C-galactosylceramide
(-C-GalCer; refs. 14 and 15), is much more active than -Gal-
Cer for inducing resistance to coadministered tumor cells and
malaria parasites. In the current study, we wanted to determine
whether the more active glycolipid -C-GalCer is a more potent
inducer of DC function in various forms of innate and adaptive
resistance.
Results
-C-GalCer Is a Distinct and More Potent Inducer of Innate Responses
in Mice. To understand the capacity of the new -C-GalCer
analogue to enhance resistance to malaria and tumors in mice
(14), we analyzed several different types of innate and adaptive
immune responses. First, we administered graded doses of each
glycolipid i.v. and monitored the innate response in terms of
elevations of serum cytokines (Fig. 1 Top). For induction of
IFN-, the response to -GalCer began to decrease at 20 ng per
mouse, whereas for -C-GalCer, 2 ng was the limiting dose (Fig.
1). Another distinction was that -C-GalCer induced more
prolonged production of IFN- and higher levels of IL-12 but did
not induce IL-4 or TNF- (Fig. 1). Thus, -C-GalCer is a more
active inducer of the innate production of cytokines than the
prototype -GalCer, and the innate response is qualitatively
different.
Distinct CD11c DC and NK Cell Populations Produce IL-12 and IFN-
After GalCer Stimulation. To determine the source of the serum
cytokines in the experiments of Fig. 1, we examined two other
responses that take place when DCs present glycolipids, i.e., the
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DCs start to produce IL-12, and this released cytokine, in turn,
mobilizes IFN--producing NK cells. We found that both of
these events could be documented with FACS assays after
administration of either -C-GalCer or -GalCer i.v. High
expression of CD11c marks DCs (16, 17), but CD11c also can be
expressed at intermediate levels on some NK cells (18–22).
CD11c cells were isolated 6 h after glycolipid injection and were
analyzed for surface markers. Two populations, CD11c DX5
and CD11c DX5, were distinguished within the T cell antigen
receptor V-negative fraction (Fig. 2A, R2 and R3). CD8086
costimulatory molecules were expressed at much higher levels on
CD11c DX5 cells (Fig. 2B), which were also MHC class II rich
(data not shown), relative to CD11c DX5 cells. Also, CD86
was up-regulated on the CD11c DX5 cells after injection of
either glycolipid (Fig. 2B). This finding indicates that DX5 cells
are DCs, whereas other CD11c cells are NK cells carrying the
DX5 NK marker (18). When intracellular cytokines were as-
sessed after 20 ng of -C-GalCer or 2 g of -GalCer i.v., some
of the CD11c DX5 NK cells preferentially produced IFN-,
not IL-12 (Fig. 2C Left). Reciprocally, a fraction of the CD11c
DX5 DCs produced IL-12p40 but little or no IFN- (Fig. 2D
Right). The IFN- producing population did not express B220
and MHC class II (data not shown) and, therefore, seems
different from the recently described subset of IFN--producing
killer DCs (19, 20). Thus, IL-12 and IFN- are produced by
distinct CD11c cells in spleen, the former by costimulatory DCs
and the latter by NK cells activated by the DC–NKT interaction.
-C-GalCer on DCs Is More Effective in Expanding Cytokine-Producing
NKT Cells. Our prior work found that -GalCer, when loaded on
DCs, elicited prolonged ‘‘priming’’ of NKT cells in spleen and
liver for 2 or more days (23). We injected either free glycolipid
or glycolipid-loaded DCs and looked 2 d later for primed NKT
cells, i.e., cells that would respond to -GalCer during a 16-h
ELISPOT assay for IFN- or IL-4 (Fig. 3 Upper and Lower,
respectively). Under these conditions, the major primed, cyto-
kine-secreting cells are known to be NKT cells (23). -C-GalCer
proved to be more potent than -GalCer, either as a free drug
or pulsed in graded doses onto DCs (Fig. 3). Even low doses of
-C-GalCer sufficed as a free drug at 20 ng per mouse. Also,
1–10 ngml -C-GalCer, as opposed to 100 ngml -GalCer, was
sufficient to load DCs (Fig. 3). Therefore -C-GalCer is a more
potent glycolipid for enhancing NKT function via DCs in vivo.
More Stable Binding of -C-GalCer to DCs and More Prolonged NKT
Responses. To better understand the potency of -C-GalCer, we
first applied -GalCer or -C-GalCer for graded times to the
DCs (2, 12, and 48 h) and assayed NKT cell expansion 5 d after
i.v. administration of the DCs to mice. -GalCer was able to
expand NKT cell numbers (measured as CD19 cells that bound
CD1d-GalCer tetramers) if added to DCs for 12 h but not 2 h,
whereas -C-GalCer loading onto DCs required just 2 h, and the
expansion at day 5 was also much greater (Fig. 4A). This finding
suggested that binding of -C-GalCer to DCs was more stable
than binding of -GalCer. To test this possibility, we added
glycolipid to DCs for 2 h, washed three times, and cultured the
cells for an additional 2 d without glycolipid in the presence of
granulocytemacrophage colony-stimulating factor to sustain
DC viability. These -C-GalCer-pulsed DCs were able to expand
NKT cell numbers to high levels 5 d after injection (Fig. 4B),
indicating that the association of -C-GalCer to DCs was stable.
Fig. 1. -C-GalCer is more potent than -GalCer at inducing an innate
cytokine response. Serum cytokines after graded doses of -GalCer (Left) or
-C-GalCer (Right) i.v., measured by sandwich ELISAs. Data are means from
four mice in two experiments.
Fig. 2. Distinct cytokine production by subsets of CD11c spleen cells. (A and
B) CD11c cells were isolated from spleen 6 h after injection of vehicle,
-C-GalCer, or -GalCer. After gating on TCR cells, we distinguished Cy5
anti-DX5 NK cells (R2) and DX5 DCs (R3) within APC-anti-CD11c cells (A)
and measured CD80 and CD86 expression (B). (C and D) As in A, but the cells
were cultured for 4 h in brefeldin A without other stimuli before staining the
R2 and R3 populations for intracellular IFN- (C) or IL-12 (D).









































We also added both -C-GalCer and -GalCer for 48 h to the
DCs, but -GalCer did not compete, as evidenced by strong NKT
cell expansion in vivo 5 d later (Fig. 4C). Thus, synthetic
glycolipids can be developed that bind more stably to DCs and
improve NKT cell expansion in vivo.
-C-GalCer Is a More Potent Inducer of Innate Resistance to B16
Melanoma. To test the in vivo efficacy of the innate response, we
used a standard assay in which the establishment of metastases
of MHC-class I low B16 melanoma cells is retarded (23). Lung
metastases were evaluated 2 weeks after coadministration i.v. of
DCs loaded with either glycolipid together with B16 melanoma
cells. The -C-GalCer-loaded DCs were more effective than
-GalCer-loaded DCs in reducing the size (Fig. 5A) and the
number of lung metastases (Fig. 5B). When mice were depleted
of NK cells by prior treatment with a polyclonal anti-asialo-GM1,
the number of metastases increased relative to untreated con-
trols, but again, DCs pulsed with -GalCer induced some
protection (Fig. 5B). This protection indicates that both NKT
and NK cells are contributing to the resistance induced by
-C-GalCer-loaded DCs and that the -C analogue is more
potent than -GalCer at mobilizing these innate mechanisms.
-C-GalCer Actively Induces Costimulatory Molecules on DCs and NKT
Cells. To further compare the consequences of -C-GalCer and
-GalCer on DC function, we assessed expression of costimu-
latory molecules on the main subsets of myeloid CD11c DCs in
spleen, distinguished as CD8 and CD8. Although 2 g of
-GalCer is typically used as an adjuvant in mice, we found that
20 ng was sufficient to induce a near-maximal up-regulation of
CD86 and B7-DC costimulatory molecules and that 20 ng of
-C-GalCer and -GalCer were equally effective by this criterion
(Fig. 6A). We also verified that the effect of -C-GalCer on the
surface markers of DCs was more potent with the i.v. rather than
i.m. and s.c. routes of administration (Fig. 8 A and B, which are
published as supporting information on the PNAS web site), and
that the effects depended on NKT cells, as assessed with mice
genetically lacking CD1d and NKT cells (Fig. 8 C and D).
However, when we examined the up-regulation of another
essential costimulator, CD40L, on NKT cells (24), we found that
20 ng of -C-GalCer was as effective as 2 g of -GalCer but
that 20 ng of -GalCer was close to inactive (Fig. 6B). Thus, by
using 20 ng of glycolipid, one has a situation in which both
compounds up-regulate the expression of B7 family costimula-
tors, but only the newer -C-GalCer up-regulates CD40L ex-
pression on NKT cells.
-C-GalCer Is a More Effective Adjuvant for Adaptive T Cell Immunity
to Tumors. Because ligation of CD40 on DCs is essential for
glycolipids to act as adjuvants for T cell immunity (24, 25), we
examined the capacity of lower doses of glycolipid to induce
Fig. 3. Enhanced cytokine-producing NKT cells after injection of free gly-
colipid or glycolipid loaded DCs. Groups of mice (x axis) were immunized i.v.
with vehicle (V), free glycolipid, or DCs that had been pulsed ex vivo with V,
-GalCer, or -C-GalCer. Two days later, spleens were analyzed with or with-
out -GalCer (100 ngml) restimulation for 16 h, and IFN- or IL-4-ELISPOT-
forming cells were counted.
Fig. 4. More stable binding of -C-GalCer to DCs. (A) Bone marrow-derived
DCs were generated for 8 d in culture (see Materials and Methods) and
exposed to -GalCer (G) or -C-GalCer (CG) during the last 2, 12, and 48 h. The
cells were washed and injected i.v. to expand CD1d-GalCer dimer-binding NKT
cells 5 d later in spleen. (B) As in A, but the DCs were loaded for 2 h with
-GalCer or -C-GalCer, washed, cultured for 48 h in granulocytemacrophage
colony-stimulating factor-supplemented medium, and injected into mice to
measure NKT cell numbers 5 d later. (C) As in B Right, but both glycolipids were
added together for 48 h to DCs before induction of NKT cell expansion in vivo.

































adaptive immunity in two previously described systems. We first
used a sensitive assay for presentation of cell-associated antigen.
In this assay, dying splenocytes loaded with ovalbumin (OVA)
are injected i.v. with graded doses of glycolipid. It was noted (6)
that coadministration of 2 g of -GalCer led to the develop-
ment of robust CD8T cell response to the cell-associated OVA
and that this induced immunity was the result of antigen
presentation by DCs maturing in response to -GalCer and NKT
cells. Here we noted that 20 ng of -C-GalCer induced a
comparable response to 2 g of -GalCer. In contrast, lowering
the dose of the parent compound -GalCer to 20 ng reduced the
T cell response, i.e., the response was only 42  17% of the
maximum observed with 2 g of glycolipid (mean of three mice),
and the response was just perceptible at 2 ng (Fig. 7A). Thus, 20
ng of -C-GalCer acts as a more potent adjuvant than -GalCer
for the presentation of cell-associated antigens in mice, even
though both induce high levels of CD86 costimulatory molecules
on DCs at this dose.
To extend the analysis to tumors, we injected irradiated J558
plasmacytoma cells i.v. rather than OVA-loaded splenocytes. It
has been shown recently that -GalCer is an effective adjuvant
for immunization of protective antitumor T cells after uptake of
irradiated MHC-negative tumor cells by DCs (25). As shown in
Fig. 7B, mice that were given irradiated J558 tumor cells and
either 20 ng of -C-GalCer or 2 g of -GalCer, but not 20 ng
of -GalCer, developed resistance to challenge with MHC class
I positive J558 tumor cells. These findings indicate that -C-
GalCer is an effective and more potent adjuvant that -GalCer
for adaptive resistance to tumor cells and that improved adjuvant
function correlates with CD40L up-regulation on the NKT cells
(Fig. 6B) and presentation of cell-associated antigen (Fig. 7A),
but not on up-regulation of CD86 (Fig. 6A).
Discussion
-GalCer, when presented on CD1d molecules of DCs to NKT
cells, induces several responses that can be protective against
tumors, as most recently described for experimental hematologic
tumors in mice (25). New analogues of -GalCer are being
synthesized, and one of these, the C-glycoside analogue of
-GalCer (-C-GalCer), was found to be more potent in helping
mice to defend against mouse malaria and B16 melanoma (14).
To understand the basis for the improved adjuvant effects of
-C-GalCer, we have studied its capacity to stimulate several
innate and adaptive immune responses, particularly at the level
of DCs.
When we compared the effects of the two synthetic glycolipids
given i.v., the -C-GalCer was more active than -GalCer, and
it induced a more prolonged IFN- and IL-12 innate response,
without IL-4 or TNF- (Fig. 1). The IFN- and IL-12 were
produced by NK and DCs, respectively (Fig. 2). Previously, we
had reported that -GalCer induced IFN- production by DCs
(24), but we overlooked the fact that the CD11c marker can be
expressed by both DCs and activated NK cells. When we loaded
the two synthetic glycolipids onto DCs ex vivo and then injected
the cells, the -C-GalCer-pulsed DCs also were able to induce
a stronger and more prolonged IFN--producing NKT response
(Fig. 3). This finding, at least in part, can be attributed to the
Fig. 5. DCs loaded with glycolipids protect against lung metastases of B16
melanoma. Micrographs (A) and numbers of melanin-laden (black) metastases
(B) in the lungs of groups of five to eight mice 14 d after B16 melanoma cells
were administered i.v. together with DCs that had been exposed beforehand
in vitro to either -GalCer (G) or -C-GalCer-(CG). We also tested mice depleted
of NK cells by anti-asialo-GM1 treatment (*, P  0.005; **, P  0.008).
Fig. 6. Up-regulation of costimulatory molecules by -C-GalCer. (A) Up-
regulation of CD86 (x axis) on CD8 and CD8 CD11c DC subsets 16 h after
injecting graded doses of -GalCer or -C-GalCer i.v. (B) Up-regulation of
CD40L on CD1d-dimer CD19 NKT cells stained for CD40L-PE, CD19-FITC, and
CD1d-dimer-biotinstreptavidin-APC 2 h after i.v. injection of -GalCer or
-C-GalCer.









































more stable association of -C-GalCer with DCs, relative to
-GalCer. Likewise -C-GalCer was more effective at inducing
adaptive protective T cell-mediated immunity to cell-associated
antigens including tumor cells, which are captured by DCs in vivo
(Fig. 7). -C-GalCer, like the parent -GalCer, required glyco-
lipid-presenting CD1d molecules and NKT cells, because DCs
from CD1d/ or J18/ mice did not show signs of maturation.
Therefore, -C-GalCer is more potent than -GalCer in allow-
ing DCs to activate both innate and adaptive limbs of immunity
in mice.
We also noted that the i.v. route was the most effective for
both glycolipids, possibly because this route allowed access of
glycolipid to DCs in the spleen, where there are relatively large
numbers of NKT cells available for interaction with DCs. A
single dose of 20 ng of -C-GalCer was sufficient to set into
motion the many innate and adaptive responses that we mea-
sured. A recent study evaluated intranasal injection of -GalCer,
which activated pulmonary IL-4-producing NKT cells along with
the development of airway hyperreactivity (26, 27). To induce
antigen-specific T cell immunity with -GalCer through the oral
route, Silk et al. (8) gave 8 g of -GalCer together with OVA
antigen. Our data indicate that the type of glycolipid and the
route of injection markedly influence the efficacy of glycolipids
as adjuvants.
We found a significant lack of correlation between the mat-
uration of DCs, as monitored by increased expression of B7
family costimulatory molecules, and the capacity of the DCs to
elicit immunity. Even at a low dose, 20 ng of -GalCer per
mouse, the DCs up-regulated CD86 and B7-DC molecules (Fig.
6), but the same mice were unable to induce strong T cell
responses to cell-associated antigens (Fig. 7). The induction of T
cell immunity in this system is known to require an interaction
of CD40L with CD40 on the DCs (7, 24), and up-regulation of
CD40L expression on NKT cells correlated much better with the
capacity of a given dose of glycolipid to act as an adjuvant (Fig.
6B). In keeping with our prior studies (24), the new data reiterate
that the up-regulation of CD86 alone is insufficient to allow
antigen-presenting DCs to initiate immunity. Other molecules,
in this case a CD40–CD40L interaction, are essential.
Our finding that a glycolipid analogue can selectively promote
Th1 type innate and adaptive responses is germane to using these
compounds to enhance resistance to certain intracellular infec-
tions and tumors. IFN- producing NKT cells are more valuable
for resistance to experimental tumors (23). Chang et al. recently
found that mature DCs loaded with -GalCer induce a pro-
longed expansion of NKT cells in patients with advanced cancer
(28). The results from our current study indicate that CD1d
analogues can be designed that are more effective in generating
an immunostimulatory DC–NKT interaction. Clinical research
will be needed to pursue the efficacy of these new glycolipids in
cancer patients.
Materials and Methods
Mice. Specific pathogen-free C57BL6 (B6), BALBc, and
TAP/ B6 female mice at 6–7 weeks were purchased from The
Jackson Laboratory (Bar Harbor, ME). Mice deleted of J281
(J18) and CD1d genes were generously provided by M. Tan-
iguchi (The Institute of Physical and Chemical Research, Yoko-
hama, Japan) and Luc Van Kaer (Vanderbilt University, Nash-
ville, TN). Mice were studied in compliance with relevant laws
and institutional guidelines.
Reagents. -C-GalCer was synthesized as described in ref. 15.
One milligram of -C-GalCer was dissolved in DMSO, and a
Fig. 7. DC-mediated T cell immunity induced by -C-GalCer. (A) B6 mice were primed with 2  107 OVA-loaded, TAP/ spleen cells and either graded doses
of -GalCer or 20 ng of -C-GalCer i.v. as described in refs. 6 and 24. Seven days later, mice were assayed for IFN--producing CD8 T cells 6 h after restimulation
with an MHC class I binding OVA peptide in brefeldin A. (B) Mice were immunized with 5  106 irradiated MHC class I negative J558 plasmacytoma cells and the
indicated doses of glycolipid i.v., as described for this system of T cell-dependent protection against tumors (25). Two weeks later, groups of five mice were
challenged s.c. with 1  106 MHC class I bearing J558 cells.

































required aliquot was then dissolved in PBS buffer, warmed to
50°C, and sonicated for a few minutes. -GalCer was kindly
provided by the Pharmaceutical Research Laboratory, Kirin
Brewery (Gunma, Japan) and diluted in PBS (6). LPS-free OVA
was from Seikagaku Corp. (Tokyo, Japan). The following mono-
clonal antibodies (mAbs) were from BD Pharmingen (San
Diego, CA): FITC-conjugated anti-CD4; FITC- or PE-
conjugated anti-CD8; APC-conjugated anti-CD11c; biotin-
ylated-isotype control; and anti-CD40, -CD80, -CD86, and
-CD119IFN-R. Biotinylated mAbs were detected with
streptavidin-APC. To identify cells producing cytokines as part
of the innate response to glycolipid, splenic CD11c cells were
labeled with PE-Cy7 anti-CD11c and APC-anti-DX5 (18) to
distinguish DX5 classical or conventional DCs from DX5 NK
cells. To identify the newly described IFN--producing killer
DX5 DCs, we used expression of MHC class II and B220 (FITC
antibodies), which are lacking from typical DX5 DC NK cells
(19, 20).
Stability of Glycolipid Binding to Bone Marrow-Derived DCs. Bone
marrow-derived DCs were generated with granulocyte
macrophage colony-stimulating factor for 8 d as described in ref.
29. DCs were pulsed with -GalCer, -C-GalCer, or both for
2–48 h. LPS also was added at day 7 for the last 16 h to drive DC
maturation. Two to five days after injection of the DCs into mice
i.v., spleen suspensions were analyzed for NKT, NK, or conven-
tional T cells (6, 23).
Flow Cytometric Assay for Cytokine Production by CD11c Spleen
Cells. As described in ref. 6, splenocytes were released by teasing
and treatment with collagenase D (Roche Diagnostics, India-
napolis, IN). CD11c cells were selected with anti-CD11c coated
magnetic beads and cultured with brefeldin A (Pharmingen) for
4 h. The cells were incubated with 2.4G2 mAb to block FcR;
washed; incubated for 30 min with FITC anti-CD8, Cy5 anti-
DX5, and APC anti-CD11c at room temperature; then washed;
permeabilized (CytofixCytoperm Plus, Pharmingen); stained
with PE-conjugated anti-IFN- (XMG1.2) or anti-IL-12 mAbs
for 15 min at room temperature; and analyzed with a FACS
Calibur (Becton Dickinson, San Jose, CA) and either CellQuest
(BD Biosciences, Mountain View, CA) or FlowJo (Tree Star,
San Carlos, CA) software.
T Cell Immunity. Mice were injected with 2  107 OVA pulsed and
osmotically shocked, syngeneic, TAP/ splenocytes as de-
scribed in ref. 30. Seven days later, 5  106 spleen cells were
cultured for 6 h in 24-well plates with 1 M OVA257–264 peptide
(for CD8 T cells) or 2 M OVA323–339 peptide (for CD4 T
cells) in the presence of brefeldin A to accumulate IFN-
intracellularly. Cells were incubated with 2.4G2 mAb, then FITC
anti-CD4 or -CD8 for 20 min at room temperature, and then
permeabilized and stained for IFN- as above.
Tumor Protection Experiments. Irradiated J558 plasmacytoma cells
(5  106 100 Gy) together with glycolipid were coadministered
to C57BL6 mice as described in ref. 25. Two weeks later, groups
of five mice were challenged s.c. with 1  106 J558 cells.
Statistical Analysis. The statistical significance of differences
between the experimental groups was determined by the Mann–
Whitney exact rank sum test. Differences in tumor protection of
each group were analyzed by using the log-rank test. P  0.05 was
considered statistically significant.
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